NCT05676853View on ClinicalTrials.gov

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

April 27, 2023

Study Completion Date

April 27, 2023

Conditions
Arginase I DeficiencyHyperargininemia
Interventions
DRUG

Pegzilarginase

Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated

Trial Locations (1)

M5G1X8

Hospital for Sick Children, Toronto

Sponsors
All Listed Sponsors
lead

Aeglea Biotherapeutics

INDUSTRY

NCT05676853 - A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency | Biotech Hunter | Biotech Hunter